ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Case Report

Case Report: Cutaneous Metastases from Colorectal Cancer: A Rare Case of Isolated Skin Recurrence

[version 1; peer review: awaiting peer review]
PUBLISHED 28 Oct 2025
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS AWAITING PEER REVIEW

This article is included in the Oncology gateway.

Abstract

Background

Cutaneous metastases from colorectal cancer (CRC) are rare, occurring in fewer than 5% of metastatic cases, and typically indicate advanced disease with poor prognosis.

Case presentation

We report the case of a 42-year-old man previously treated with curative surgery and adjuvant chemotherapy for rectosigmoid adenocarcinoma. Eighteen months after completion of therapy, he presented with pruritic eczematous skin lesions in the right inguinal fold, gluteal region, and perianal area. Biopsy revealed metastatic adenocarcinoma of colorectal origin (CK20-positive/CK7-negative). Restaging CT scan demonstrated new non-necrotic lymphadenopathy at the aortic bifurcation and bilateral internal iliac chains, without visceral metastases. The disease was classified as unresectable metastatic recurrence (stage IV). The patient was referred for palliative systemic therapy, with molecular profiling (RAS/BRAF/MSI) to guide treatment.

Conclusions

Cutaneous metastases are an uncommon manifestation of CRC recurrence and may mimic benign dermatologic conditions. Prompt biopsy of atypical skin lesions in CRC survivors is crucial for early detection. Systemic therapy remains the cornerstone of management, guided by molecular features. Emerging immunotherapy and anti-angiogenic combinations offer potential benefit even in microsatellite-stable disease.

Keywords

Colorectal cancer; Cutaneous metastasis; Skin metastasis; Rectosigmoid adenocarcinoma; Case report

Introduction

Cutaneous metastases from colorectal cancer (CRC) are rare, with reported incidences of 0.7–4% among metastatic cases. Their presence generally reflects advanced disease and poor prognosis. Typical metastatic sites include the liver, lungs, and peritoneum; skin involvement is far less common.

We present an unusual case of isolated cutaneous recurrence revealing systemic relapse after curative treatment for a rectosigmoid junction adenocarcinoma.

Case presentation

A 42-year-old man with no prior medical history underwent surgery for a stenosing adenocarcinoma of the rectosigmoid junction.

Initial locoregional and distant staging was negative. He underwent low anterior resection with stapled colorectal anastomosis and had an uncomplicated postoperative recovery.

Histopathological examination of the resected specimen showed a moderately differentiated adenocarcinoma, staged as ypT3N1b. The patient received eight cycles of adjuvant capecitabine (Xeloda), completed 18 months after surgery.

A follow-up CT scan performed three months after completion of chemotherapy showed no abnormalities. A completion colonoscopy, performed because a full preoperative evaluation had not been possible, was also normal.

Approximately five months later, the patient presented with newly developed pruritic skin lesions. Clinical examination revealed erythematous eczematous plaques in the right inguinal fold, gluteal region, and perianal area ( Figure 1). He was otherwise in good general condition (ECOG 0). Digital rectal examination was unremarkable, and serum tumor markers (CEA, CA 19-9) were within normal limits.

64715e89-9464-4c45-ba2d-efa82f4b29c2_figure1.gif

Figure 1. Clinical presentation of cutaneous metastases: infiltrating nodular lesions in inguinal and peri anal regions on examination.

A punch biopsy of the skin lesion confirmed metastatic adenocarcinoma consistent with colorectal origin (CK20-positive, CK7-negative, CDX2-positive) ( Figure 2A,B).

64715e89-9464-4c45-ba2d-efa82f4b29c2_figure2.gif

Figure 2. Histopathological and immunohistochemical features of the cutaneous metastasis: (A) Skin biopsy showing dermal infiltration by atypical glandular structures consistent with metastatic adenocarcinoma (Hematoxylin–Eosin, ×200). The asterisk (*) marks tumoral glands invading the dermis, while the arrow indicates adjacent uninvolved dermis. (B) Immunohistochemical staining showing diffuse cytoplasmic positivity for CK20 in tumor cells, confirming colorectal origin (CK20 IHC, ×200).

A thoraco-abdomino-pelvic CT scan revealed new, non-necrotic lymphadenopathy at the aortic bifurcation (22 × 9 mm) and in both internal iliac chains ( Figure 3).

64715e89-9464-4c45-ba2d-efa82f4b29c2_figure3.gif

Figure 3. Contrast-enhanced CT scan shows non necrotic lymphadenopathy at the aortic bifurcation (22 × 9 mm).

The case was discussed in a multidisciplinary tumor board. The presence of cutaneous metastases and retroperitoneal lymph node involvement led to classification as unresectable stage IV disease. The patient was referred for palliative systemic chemotherapy, with RAS, BRAF, and MSI testing planned to guide targeted or immunotherapeutic options.

Discussion

Cutaneous metastases from CRC are uncommon but clinically significant indicators of systemic dissemination. The median time from initial diagnosis to skin involvement ranges from 18–30 months, and median survival after diagnosis of skin metastasis is approximately 8 months.13

Sites and mechanisms

Skin metastases typically involve the abdominal wall, perineal, or perianal regions, often following surgical scars or areas of venous/lymphatic drainage from the primary tumor.1,2 In our patient, the inguinal and perianal lesions likely reflected pelvic lymphatic spread from the rectosigmoid area.

Clinical presentation and diagnosis

Cutaneous metastases may present as nodules, plaques, or inflammatory-like or eczematous lesions that mimic benign dermatoses, delaying diagnosis.35

Histopathology with immunohistochemistry (CK20+, CK7–, and CDX2+) is essential for confirming colorectal origin. Tumor markers such as CEA and CA 19-9 may remain normal, limiting their diagnostic value in isolation.

Management

Treatment is mainly palliative and depends on molecular profile and disease extent:

  • RAS/BRAF wild-type tumors: Chemotherapy (FOLFOX or FOLFIRI) plus anti-EGFR agents (cetuximab or panitumumab).

  • MSI-high/dMMR tumors: Immune checkpoint inhibitors (pembrolizumab, nivolumab ± ipilimumab).

  • RAS/BRAF-mutant or MSS/pMMR tumors: Chemotherapy combined with anti-angiogenic therapy (e.g. bevacizumab).

For symptomatic relief, surgical excision or palliative radiotherapy can alleviate pain, bleeding, or ulceration, while topical or systemic antipruritic agents may improve comfort.

Emerging strategies

Recent studies have reported clinical activity from combinations of immune checkpoint inhibitors with anti-angiogenic tyrosine kinase inhibitors (e.g. regorafenib, fruquintinib) in microsatellite-stable CRC, suggesting new therapeutic avenues.68

Conclusion

Cutaneous metastases from colorectal cancer are rare and often signal systemic relapse. Awareness of this entity is essential, as lesions may mimic benign dermatologic conditions and occur even when tumor markers and imaging appear normal. Early biopsy and multidisciplinary evaluation are critical for accurate diagnosis and management.

Systemic therapy guided by molecular profiling remains the mainstay of treatment, while novel immunotherapy–anti-angiogenic combinations show promise in refractory microsatellite-stable disease. Continued reporting of such cases will aid in refining prognostic understanding and therapeutic strategies.

Patient consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 28 Oct 2025
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Khedhiri N, Mbarek A, Hlel I et al. Case Report: Cutaneous Metastases from Colorectal Cancer: A Rare Case of Isolated Skin Recurrence [version 1; peer review: awaiting peer review]. F1000Research 2025, 14:1172 (https://doi.org/10.12688/f1000research.172051.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status:
AWAITING PEER REVIEW
AWAITING PEER REVIEW
?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 28 Oct 2025
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.